Recently, I started a patient on high-dose buprenorphine because he could no longer get to his methadone clinic. He lost his leg this year to xylazine-associated wounds. The amputation was not the result of a single dramatic overdose, but of months of progressive tissue necrosis from repeated exposure to fentanyl adulterated with “tranq.” The infection spread. The vascular compromise worsened. Eventually there was nothing left to salvage. He now moves with difficulty. Public transportation is unreliable. The methadone clinic that once structured his week is physically out of reach.
So we adapted. We escalated buprenorphine more aggressively than I might have several years ago, recognizing the potency of the current fentanyl supply and the instability of his circumstances. His addiction is being managed in a primary care exam room, but its origins stretch far beyond it.
Cartel headlines vs. clinical realities
On the same day that I adjusted his dose, news broke that Nemesio Oseguera Cervantes, known as “El Mencho,” the alleged leader of the Jalisco New Generation Cartel, had been killed in Mexico. For many, that headline signals justice, disruption, or progress in the so-called war on drugs. For those of us working in addiction medicine, it raises a more complicated question: What, if anything, will change for the patient in front of me?
If we want to understand why we are initiating higher and higher doses of buprenorphine in primary care settings to be effective, we must look beyond prescribing patterns and toward the realities of a synthetic opioid market that is agile, global, and largely indifferent to symbolic victories.
The agility of synthetic opioid markets
Fentanyl is not heroin. It does not depend on agricultural cycles or fixed trafficking corridors. It is synthesized, compact, potent in micrograms, and easily redistributed. When enforcement pressure increases in one region, supply chains shift. When a leader falls, another structure emerges. Markets respond faster than policy. The modern overdose crisis is shaped less by demand than by volatility in supply.
Patients are no longer using a relatively predictable product. They are navigating a chemical roulette wheel. Fentanyl analogues appear and disappear. Xylazine infiltrates regional markets, producing wounds and sedation that naloxone cannot reverse. New synthetic compounds surface faster than toxicology screens can adapt. The instability itself becomes lethal.
High-dose buprenorphine as an adaptation
Clinically, this translates into higher tolerance, more frequent precipitated withdrawal, and the need for induction strategies that would have seemed excessive a decade ago. High-dose buprenorphine is not a sign of therapeutic failure; it is an adaptation to a stronger and less forgiving drug environment. We are treating not just opioid use disorder, but the consequences of an increasingly synthetic and adulterated supply.
Why supply-side disruption is not enough
Meanwhile, public discourse often remains anchored to familiar narratives: personal responsibility, moral failing, cartel kingpins, and border control. These conversations may carry political weight, but they rarely map onto the day-to-day realities of outpatient care. My patient’s amputation was not prevented by a headline. It was not reversed by an arrest. It was shaped by repeated exposure to a contaminated and potent drug supply that is responsive to profit, not symbolism.
This does not mean enforcement is irrelevant. It means that supply-side disruption alone has never been sufficient. When one pathway closes, another opens. When heroin became scarce or inconsistent, fentanyl filled the void. When prescription opioids were curtailed without adequate treatment expansion, illicit markets expanded to meet persistent demand. The market does what markets do: It adapts.
Carlos N. Hernandez-Torres is a family medicine and addiction medicine physician.
